Preclinical systematic reviews are vital; they serve many purposes by assessing the range and quality of the evidence. Through these reviews knowledge gaps can be identified, methodological quality improved, unnecessary duplication of experiments can be avoided, and clinical trial design can be informed.
This article by Alexandra Bannach-Brown and colleagues discusses the past and present technological development efforts in this domain, shows the extent to which recent technological advances have impacted the preclinical systematic review pipeline and what challenges we still face.
The ultimate aspiration is to be able to integrate new evidence into systematic reviews of existing evidence, so that decisions are informed by our most up-to-date understanding, in a ‘living evidence’ summary.